Why Trust Ikris for Cancer Medicine Export?
Why Trust Ikris for Cancer Medicine Export?
Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last updated: September 2026
Quick answer
Ikris Pharma Network is a pharmaceutical sourcing and distribution company, founded in India in 2014, that helps doctors, hospitals and importers obtain cancer medicines that are unavailable, unapproved or in short supply in their own country. Buyers trust it because it operates a GDP-certified warehouse in Belgium, holds written authorisations from several global drug makers, ships temperature-sensitive products through a validated cold chain, and supplies every order with batch-level paperwork that can be checked independently.
A cancer diagnosis rarely comes with a guarantee that the right medicine will be on the pharmacy shelf. A drug may be approved in the United States or Europe but not yet registered at home. A hospital may face a sudden shortage of a chemotherapy injection. An importer may find a supplier with an attractive price and no way to prove where the stock came from.
This guide explains, in plain terms, what Ikris Pharma Network actually does for patients and for international buyers of oncology medicines, which parts of the world it supplies, and the specific, checkable reasons companies choose to work with it. Where a claim comes from the company's own records, we say so, so you can ask for proof.
Who Is Ikris Pharma Network?
Ikris Pharma Network (IPN) is not a drug manufacturer. It is a specialist in the part of healthcare most people never see: finding a genuine, correctly stored medicine and moving it legally across borders to the patient who needs it. The founder started the business after close to three decades in the pharmaceutical industry, working with multinational and leading Indian drug companies. You can read the full company story and leadership team.
| Fact | Details |
|---|---|
| Founded | August 2014, Noida, India |
| Founder and CEO | Praveen Sikri |
| Offices and entities | India (Noida), Belgium (Andrimont), Bulgaria (Sofia), Hong Kong |
| What it does | Named-patient supply of unapproved medicines, export of Indian generics, clinical trial comparator sourcing, real-world data |
| Therapy areas | Oncology, hematology, hepatology, neurology, transplant, immunology, nephrology and rare diseases |
| Reach (company-reported) | 150+ countries served and 10,000+ patients supported |
| Support | 24/7, 365 days a year, with a specialist cold-chain logistics team |
How Does Ikris Help Cancer Patients?
Most families reach IPN at a stressful point: the oncologist has named a treatment, and nobody locally can supply it. The help depends on why the medicine is out of reach.
When the medicine is not approved in your country
Many countries allow a doctor to import an unregistered medicine for one specific patient with a serious or life-threatening illness, when no approved alternative works. The name differs by country: named-patient import, compassionate use, special access or expanded access. In India the route sits under the New Drugs and Clinical Trials Rules, 2019. In the European Union it rests on Article 5(1) of Directive 2001/83/EC. Through its named-patient import service, IPN handles the practical work around that legal route:
1. Doctor's request
The treating oncologist sends the prescription and a short medical justification. IPN acknowledges the request by email within one business day.
2. Paperwork and permission
IPN prepares the supplier documents the regulator asks for, so the doctor or hospital can apply for the import permission required locally.
3. Authorised sourcing
The product is bought from the manufacturer or its authorised wholesale chain, never from unverified traders.
4. Cold-chain delivery
Temperature-sensitive products travel in validated packaging with temperature logging from dispatch to hospital.
5. Ongoing support
Refill planning, and a pharmacovigilance-trained team to record any side effects reported during treatment.
When the medicine is approved but hard to get or too costly
Sometimes the problem is supply or price, not approval. India produces quality-assured generic versions of many established chemotherapy and targeted cancer drugs, often at a fraction of the originator price. Through its Indian generics export desk, IPN sources these directly from WHO-GMP manufacturers, which keeps shelf life long and removes layers of middlemen.
What IPN will not do
Trust is also about limits. IPN does not prescribe, does not sell prescription cancer drugs without a valid prescription, and cannot bypass a country's import rules. It cannot promise that a regulator will approve a request. Any company that promises otherwise is a warning sign.
Which Countries Does Ikris Export Cancer Medicines To?
IPN reports supplying medicines to more than 150 countries. Oncology supply is concentrated in the regions below. Whether a particular medicine can be sent to a particular country always depends on that country's import law, so treat this as a map of where the company is active, not a promise for every product.
| Region | Examples of markets served | How supply usually works |
|---|---|---|
| South Asia | India, Nepal, Sri Lanka | Named-patient import of medicines not registered locally; export of Indian generics |
| Latin America | Brazil, Mexico, Chile, Colombia | Specialty and oncology distribution; Brazil has been supplied for over ten years |
| Europe | Belgium, Bulgaria, Germany and wider EU | EU-sourced medicines shipped from EU hubs under Good Distribution Practice |
| Middle East and GCC | UAE and neighbouring Gulf markets | Hospital and distributor supply; named-patient requests |
| Africa | Nigeria and other West and East African markets | Generic oncology and supportive-care medicines for importers and tenders |
| Asia-Pacific and CIS | Southeast Asia, Central Asia, Hong Kong hub | Distributor supply routed through the Hong Kong entity where useful |
Brazil is a good example of how long these relationships run. Its regulator, ANVISA, is strict, and IPN's record there is described in our piece on more than a decade of supply into Brazil.
Why Do International Companies Trust Ikris?
Procurement teams do not buy on promises. They buy on evidence they can check. These are the reasons buyers give, and the evidence behind each one.
1. A certified European warehouse
In 2016 IPN set up Ikris Pharma International in Belgium and received a Good Distribution Practice (GDP) certificate from the Belgian Federal Agency for Medicines and Health Products for its pharmaceutical warehouse. GDP is the rulebook for storing and moving medicines without damaging them; the global benchmark is the WHO guideline on good storage and distribution practices (TRS 1025, Annex 7). A regulator-inspected site in the EU is something a buyer can verify, not just take on trust.
2. Written authorisations from drug makers
Several global manufacturers have formally authorised IPN to provide access to their medicines in India through named-patient import. In oncology, that includes Gilead Sciences, for specific therapies in HR-positive/HER2-negative and triple-negative metastatic breast cancer, and Servier. Rare-disease partners include BioMarin, PTC Therapeutics, Sarepta, Alexion, Santhera and Recordati Rare Diseases. The full list is on our manufacturer partners page.
Why an authorisation matters
When the maker of a drug names a distributor, the stock comes straight from the source. That removes the grey-market step where most quality problems start.
3. Protection against fake medicines
Falsified cancer drugs are not a rare risk. A 2017 WHO study estimated that about 1 in 10 medical products in low- and middle-income countries is substandard or falsified, and cancer medicines were among the products reported. IPN buys only through authorised channels, keeps batch-level traceability, and follows EU serialization rules where they apply. We explain the wider problem in our article on how counterfeit drugs enter the supply chain.
4. A cold chain built for biologics
Monoclonal antibodies and many injectables must stay between 2 and 8 degrees Celsius. One warm afternoon on an airport tarmac can ruin a shipment. IPN specialises in cold-chain shipments and uses validated packaging with temperature data loggers, so the receiving pharmacist can see the whole temperature history before accepting the box.
5. Paperwork that clears customs
Delays at the border are one of the biggest hidden costs in oncology supply. A typical IPN export shipment carries:
- Certificate of Analysis (CoA) for the exact batch
- Certificate of Origin and, where needed, a Free Sale Certificate
- Commercial invoice and packing list matching the batch and expiry
- Temperature log for cold-chain products
- Supporting documents for the importing country's permission, on request
6. A team trained in compliance
IPN's staff are trained in pharmacovigilance, anti-bribery and anti-corruption (ABAC) rules, patient data privacy and business compliance. That matters to multinational partners, who can only work with distributors that pass their own due-diligence audits.
7. Visible in the industry
IPN meets partners in person at major trade events, including Expopharm in Munich and CPHI Milan in October 2026. It also runs an annual breast cancer awareness run in Noida, now in its fifth edition.
How Can a Buyer Check Any Oncology Exporter?
Whether you work with IPN or anyone else, these questions separate genuine suppliers from risky ones. A good supplier will answer all of them without hesitation.
Questions to ask before the first order
- Can you share your wholesale or GDP licence, and which authority issued it?
- Where exactly will this batch come from, and can you show the chain back to the manufacturer?
- Will I receive the CoA before dispatch, and does its batch number match the packs?
- How is temperature controlled and recorded in transit?
- Who handles a complaint, a recall or a reported side effect?
Red flags
Prices far below the market, no named source, reluctance to share licences, or an offer to ship a prescription cancer drug with no prescription.
Tip for hospital pharmacists
Keep the CoA, the temperature log and the invoice together in the patient's supply file. It makes audits and any later safety reporting much simpler.
For a broader view of the product categories IPN handles, including chemotherapy, targeted therapy, immunotherapy and supportive care, see our oncology supply range.
What Happens After You Contact Ikris?
Share the requirement
Medicine name, strength, quantity, destination country, and whether it is for a named patient or for bulk supply.
Availability and quote
The team confirms the source, shelf life, lead time and the documents your country needs.
Documents and permission
For named-patient orders, the doctor or hospital secures the local import permission using the paperwork IPN provides.
Dispatch and tracking
The order ships with batch documents and, for cold-chain items, a temperature logger.
After delivery
Reorder planning and safety follow-up. Patients and doctors can also report a suspected side effect directly through the adverse event reporting page on our website.
Frequently Asked Questions
Is Ikris Pharma Network a genuine company?
Yes. It was founded in Noida, India, in August 2014 and has registered entities in Belgium, Bulgaria and Hong Kong. Its Belgian warehouse holds a GDP certificate from the national medicines regulator, and several global drug makers have authorised it to supply their medicines.
Can Ikris send cancer medicine to my country?
In most cases, yes, if your country's law allows the import. IPN reports supplying over 150 countries. For an unapproved medicine, your doctor usually needs a named-patient import permission first. Patients in India can follow our step-by-step guide to importing unapproved medicines.
Does Ikris manufacture cancer drugs?
No. IPN sources and distributes medicines made by the original manufacturers or by WHO-GMP-certified generic makers. It does not produce drugs itself.
Can a patient buy directly from Ikris without a prescription?
No. Prescription cancer medicines are supplied only against a valid prescription and, where required, a regulatory import permission.
How does Ikris make sure a medicine is not fake?
It buys only from manufacturers or their authorised wholesalers, keeps batch-level traceability, and sends a Certificate of Analysis with each batch.
How long does a named-patient cancer medicine take to arrive?
It depends mainly on how quickly the local import permission is granted. Once permission is in hand, stocked products usually move within days. The team confirms a realistic timeline with the quote.
How do I contact Ikris for an oncology enquiry?
Message the team on WhatsApp at +91 98104 69557, call the toll-free line 1800 1200 365, or email info@ikrispharmanetwork.com. Support runs 24/7.
Need a cancer medicine that is hard to find?
Tell us the medicine, strength and destination country. Our oncology team replies within one business day, 24/7.
Toll-free: 1800 1200 365 | Phone: +91 96548 60915 | Email: info@ikrispharmanetwork.com
Disclaimer
This article describes the services of Ikris Pharma Network for general information. It is not medical advice. Treatment decisions belong to your oncologist. Import rules differ from country to country and change over time. Company figures marked company-reported come from Ikris Pharma Network's own records. The full disclaimer is available in the website footer.
Sources
- Ikris Pharma Network: company timeline, offices, partners and service pages (ikrispharmanetwork.com), accessed September 2026
- World Health Organization. 1 in 10 medical products in developing countries is substandard or falsified. News release, 28 November 2017
- World Health Organization. Good storage and distribution practices for medical products, TRS 1025, Annex 7, 2020
- Government of India, CDSCO. New Drugs and Clinical Trials Rules, 2019
- European Union. Directive 2001/83/EC on medicinal products for human use, Article 5(1)